Pharmacie sans ordonnance livraison rapide 24h: acheter viagra en ligne en France.

Liquamicina

MATERIAL SAFETY DATA SHEET
1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION MDL INFORMATION SYSTEMS,
EMERGENCY TELEPHONE
1281 Murfreesboro Road, Suite 300
1-800-424-9300 (NORTH AMERICA)
Nashville, TN 37217-2423
1-703-527-3887 (INTERNATIONAL)
1-615-366-2000

SUBSTANCE: OXYTETRACYCLINE HYDROCHLORIDE
TRADE NAMES/SYNONYMS:

CHEMICAL FAMILY: antibiotic/antiseptic
CREATION DATE: Jun 19 1986
REVISION DATE: Mar 17 2005
2. COMPOSITION, INFORMATION ON INGREDIENTS COMPONENT: OXYTETRACYCLINE HYDROCHLORIDE
CAS NUMBER: 2058-46-0
EC NUMBER (EINECS): 218-161-2
PERCENTAGE: 100
NFPA RATINGS (SCALE 0-4): HEALTH=0 FIRE=0 REACTIVITY=0
EMERGENCY OVERVIEW:
CHANGE IN APPEARANCE: darkens on exposure to moisture, hygroscopic
COLOR: yellow
PHYSICAL FORM: crystals, powder
ODOR: odorless
MAJOR HEALTH HAZARDS: No significant target effects reported.
POTENTIAL HEALTH EFFECTS:
INHALATION:
SHORT TERM EXPOSURE: irritation
LONG TERM EXPOSURE: no information is available
SKIN CONTACT:
SHORT TERM EXPOSURE: irritation
LONG TERM EXPOSURE: same as effects reported in short term exposure
EYE CONTACT:
SHORT TERM EXPOSURE: no information is available
LONG TERM EXPOSURE: no information is available
INGESTION:
SHORT TERM EXPOSURE: vomiting, digestive disorders, irregular heartbeat
LONG TERM EXPOSURE: tooth discoloration, kidney damage, tumors
CARCINOGEN STATUS:
OSHA: No
NTP: No
IARC: No
INHALATION: If adverse effects occur, remove to uncontaminated area. Give artificial respiration if not breathing. Get immediate
medical attention.
SKIN CONTACT: Wash skin with soap and water for at least 15 minutes while removing contaminated clothing and shoes. Get
medical attention, if needed. Thoroughly clean and dry contaminated clothing and shoes before reuse.
EYE CONTACT: Flush eyes with plenty of water for at least 15 minutes. Then get immediate medical attention.
INGESTION: If swallowed, drink plenty of water, do NOT induce vomiting. Get immediate medical attention. Induce vomiting
only at the instructions of a physician. Do not give anything by mouth to unconscious or convulsive person.
NOTE TO PHYSICIAN: For ingestion, consider gastric lavage, activated charcoal slurry and catharsis.
FIRE AND EXPLOSION HAZARDS: Negligible fire hazard.
EXTINGUISHING MEDIA: regular dry chemical, carbon dioxide, water, regular foam
Large fires: Use regular foam or flood with fine water spray.
FIRE FIGHTING: Move container from fire area if it can be done without risk. Do not scatter spilled material with high-pressure
water streams. Dike for later disposal. Use extinguishing agents appropriate for surrounding fire. Avoid inhalation of material or
combustion by-products. Stay upwind and keep out of low areas.
WATER RELEASE:
Subject to California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65). Keep out of water supplies and
sewers.
OCCUPATIONAL RELEASE:
Collect spilled material in appropriate container for disposal. Keep out of water supplies and sewers. Keep unnecessary people
away, isolate hazard area and deny entry.
STORAGE: Store and handle in accordance with all current regulations and standards.
8. EXPOSURE CONTROLS, PERSONAL PROTECTION EXPOSURE LIMITS:
OXYTETRACYCLINE HYDROCHLORIDE:
No occupational exposure limits established.
VENTILATION: Provide local exhaust ventilation system. Ensure compliance with applicable exposure limits.
EYE PROTECTION: Wear splash resistant safety goggles. Provide an emergency eye wash fountain and quick drench shower in
the immediate work area.
CLOTHING: Wear appropriate chemical resistant clothing.
GLOVES: Wear appropriate chemical resistant gloves.
RESPIRATOR: Under conditions of frequent use or heavy exposure, respiratory protection may be needed. Respiratory protection
is ranked in order from minimum to maximum. Consider warning properties before use.
Any dust and mist respirator with a full facepiece.
Any air-purifying respirator with a full facepiece and a high-efficiency particulate filter.
Any powered, air-purifying respirator with a tight-fitting facepiece and a high-efficiency particulate filter.
For Unknown Concentrations or Immediately Dangerous to Life or Health -
Any supplied-air respirator with full facepiece and operated in a pressure-demand or other positive-pressure mode in combination
with a separate escape supply.
Any self-contained breathing apparatus with a full facepiece.
PHYSICAL STATE: solid
COLOR: yellow
CHANGE IN APPEARANCE: darkens on exposure to moisture, hygroscopic
PHYSICAL FORM: crystals, powder
ODOR: odorless
TASTE: bitter taste
MOLECULAR WEIGHT: 496.94
MOLECULAR FORMULA: C22-H24-N2-O9.H-CL
BOILING POINT: Not applicable
MELTING POINT: Not available
DECOMPOSITION POINT: 356 F (180 C)
VAPOR PRESSURE: Not applicable
VAPOR DENSITY: Not applicable
SPECIFIC GRAVITY: Not available
WATER SOLUBILITY: soluble
PH: 2.5 (1% solution)
VOLATILITY: Not applicable
ODOR THRESHOLD: Not available
EVAPORATION RATE: Not applicable
COEFFICIENT OF WATER/OIL DISTRIBUTION: Not available
SOLVENT SOLUBILITY:
Soluble: ethanol, methanol
Insoluble: ether, chloroform
REACTIVITY: Stable at normal temperatures and pressure.
CONDITIONS TO AVOID: Avoid heat, flames, sparks and other sources of ignition. Avoid contact with incompatible materials.
INCOMPATIBILITIES: bases
OXYTETRACYCLINE HYDROCHLORIDE:
SOLUTIONS HAVING PH BELOW 2: Diminished potency.
ALKALI HYDROXIDE SOLUTIONS: Rapidly destroyed.
HAZARDOUS DECOMPOSITION:
Thermal decomposition products: acid halides, oxides of nitrogen
POLYMERIZATION: Will not polymerize.
OXYTETRACYCLINE HYDROCHLORIDE:
TOXICITY DATA:
800 mg/kg subcutaneous-rat LD50; 302 mg/kg intravenous-rat LD50; 6696 mg/kg oral-mouse LD50; 600 mg/kg subcutaneous-
mouse LD50; 100 mg/kg intravenous-mouse LD50; 100 mg/kg intravenous-dog LDLo; 80 mg/kg intravenous-rabbit LDLo; 108
gm/kg/14 day(s) continuous oral-rat TDLo; 129 gm/kg/14 day(s) continuous oral-mouse TDLo; 21000 mg/kg/10 day(s) intermittent
oral-mouse TDLo; 21000 mg/kg/10 day(s) intermittent oral-mouse TDLo; 13250 mg/kg/10 day(s) intermittent oral-mouse TDLo;
7200 mg/kg/6 day(s) intermittent oral-rat TDLo; 12000 mg/kg/10 day(s) intermittent oral-rat TDLo
CARCINOGEN STATUS: In 2 year feeding studies, there was equivocal evidence of carcinogenicity for male and female rats and
no evidence of carcinogenicity for male or female mice (NTP TR 315).
ACUTE TOXICITY LEVEL:
Slightly Toxic: ingestion
MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: kidney disorders, liver disorders
TUMORIGENIC DATA:
1802 gm/kg oral-rat TDLo/2 year(s); 2163000 mg/kg oral-rat TDLo/103 week(s) continuous; 1802500 mg/kg oral-rat TDLo/103
week(s) continuous
MUTAGENIC DATA:
DNA adduct - Bacillus subtilis 10 umol/L; DNA adduct - other microorganisms 10 mg/L; DNA adduct - other microorganisms 10
umol/L; micronucleus test - mouse oral 100 mg/kg 24 hour(s)-intermittent; specific locus test - mouse lymphocyte 200 mg/L; DNA
adduct - mammal lymphocyte 20 mg/L; unscheduled DNA synthesis - mammal lymphocyte 20 mg/L
REPRODUCTIVE EFFECTS DATA:
20 mg/kg parenteral-woman TDLo 20 week(s) pregnant female continuous; 11250 mg/kg oral-rat TDLo 6-15 day(s) pregnant
female continuous; 12 gm/kg oral-rat TDLo 6-15 day(s) pregnant female continuous; 21 gm/kg oral-mouse TDLo 6-15 day(s)
pregnant female continuous; 900 mg/kg subcutaneous-mouse TDLo 10-18 day(s) pregnant female continuous; 21 gm/kg oral-mouse
TDLo 6-15 day(s) pregnant female continuous; 13.3 gm/kg oral-mouse TDLo 6-15 day(s) pregnant female continuous; 12 gm/kg
oral-rat TDLo 6-15 day(s) pregnant female continuous
ADDITIONAL DATA: Interactions with drugs may occur.
HEALTH EFFECTS:
INHALATION:
ACUTE EXPOSURE:
OXYTETRACYCLINE HYDROCHLORIDE: No data available. Dusts may irritate mucous membranes.
CHRONIC EXPOSURE:
OXYTETRACYCLINE HYDROCHLORIDE: No data available.
SKIN CONTACT:
ACUTE EXPOSURE:
OXYTETRACYCLINE HYDROCHLORIDE: No data available. However, oxytetracycline may cause skin irritation in some
individuals. There is a possibility of sensitization reactions in individuals who have exhibited hypersensitivity to tetracyclines.
CHRONIC EXPOSURE:
OXYTETRACYCLINE HYDROCHLORIDE: When used topically, oxytetracycline hydrochloride may cause sensitization.
However, repeated oral exposures to oxytetracycline has produced dermatitis, photo-onycholysis and porphyria-like cutaneous
changes.
EYE CONTACT:
ACUTE EXPOSURE:
OXYTETRACYCLINE HYDROCHLORIDE: No data available. However 1% tetracycline in an ointment caused no detectable
injury to rabbit's eyes.
CHRONIC EXPOSURE:
OXYTETRACYCLINE HYDROCHLORIDE: No data available.
INGESTION:
ACUTE EXPOSURE:
OXYTETRACYCLINE HYDROCHLORIDE: A dose of 6696 mg/kg was lethal in mice. Tetracyclines may cause nausea,
gastrointestinal irritation, vomiting, abdominal pain, esophageal ulcers, epigastric pain and burning, diarrhea, dysphagia,
enterocolitis, anorexia, uremia, pancytopenia, acidosis, hyperkalemia, and cardiac arrhythmias. Large oral doses may cause
hypersensitivity, phototoxic, nephrotoxic, and hepatotoxic reactions in humans previously exposed to tetracyclines.
CHRONIC EXPOSURE:
OXYTETRACYCLINE HYDROCHLORIDE: In 14 day feed studies, a reduction in mean body weights and feed consumption was
noted in rats and mice at 100,000 ppm. The study indicated that males were more sensitive than females to the effects; no deaths
were reported. In 13 week studies, mean body weight reduction was noted in mice at 50,000 ppm. No deaths occurred but a fatty
metamorphosis of the liver was observed in male rats. In a 2 year study, no significant toxic effect was noted, nor was survival
affected. However, pheochromocytomas of the adrenal gland occurred with a positive trend in male rats and an increased incidence
of adenomas of the pituitary gland in female rats was recorded. An increased incidence of mammary adenofibromas was observed in
female rats. The average survival time for rats receiving oxytetracycline hydrochloride was 11% greater than that of the controls.
Reproductive effects have been reported in animals. Use of oxytetracyclines is associated with 3 kinds of renal disease: Acute non-
oliguric renal failure in persons with pancreatitis or fatty liver; uremia, in persons with previously impaired renal function; and a
falconi-like syndrome, usually associated with outdated or degraded tetracyclines. Tetracyclines tend to be deposited in the bones
and the teeth at sites of active calcification. Prolonged use has caused discoloration of the teeth and a 40% depression of bone
growth in neonates, infants and children. Sensitization reactions may occur, characterized by burning of the eyes, jaundice, fatty
liver, cheilosis, glossitis, pruritus, conjunctivitis, dermatitis, eosinophilia, leukocytosis, thrombocytopenic puppura, and
photosensitivity manifested by exaggerated sunburn. Cross-sensitization is common among the various tetracyclines. In persons
with impaired renal function, high serum levels of tetracycline may lead to azotemia, hyperphosphatemia, acidosis, and in infants
tense bulging of the fontanels. Tetracyclines may cause benign intracranial hypertension with papilledema and retinal hemorrhages;
this may occur more frequently in children than adults. Pregnant women appear to be more susceptible to severe hepatic damage.
Tetracyclines may interfere with Vitamin K synthesis and blood coagulation. Repeated use of antibiotics may lead to the
development of vaginal, oral, pharyngeal, intestinal and systemic suprainfections due to overgrowth of organisms not affected by
the antibiotic agent. In some cases, these organisms produce toxins that cause severe vomiting, diarrhea and circulatory collapse.
ECOTOXICITY DATA:
FISH TOXICITY: <200000 ug/L 96 hour(s) LC50 (Mortality) Lake trout, siscowet (Salvelinus namaycush)
ENVIRONMENTAL SUMMARY: Harmful to aquatic life.
Dispose in accordance with all applicable regulations. U.S. DEPARTMENT OF TRANSPORTATION: No classification assigned.
CANADIAN TRANSPORTATION OF DANGEROUS GOODS: No classification assigned.
LAND TRANSPORT ADR: No classification assigned.
LAND TRANSPORT RID: No classification assigned.
AIR TRANSPORT IATA: No classification assigned.
AIR TRANSPORT ICAO: No classification assigned.
MARITIME TRANSPORT IMDG: No classification assigned.
U.S. REGULATIONS:
CERCLA SECTIONS 102a/103 HAZARDOUS SUBSTANCES (40 CFR 302.4): Not regulated.
SARA TITLE III SECTION 302 EXTREMELY HAZARDOUS SUBSTANCES (40 CFR 355.30): Not regulated.
SARA TITLE III SECTION 304 EXTREMELY HAZARDOUS SUBSTANCES (40 CFR 355.40): Not regulated.
SARA TITLE III SARA SECTIONS 311/312 HAZARDOUS CATEGORIES (40 CFR 370.21):
ACUTE: No
CHRONIC: No
FIRE: No
REACTIVE: No
SUDDEN RELEASE: No
SARA TITLE III SECTION 313 (40 CFR 372.65): Not regulated.
OSHA PROCESS SAFETY (29CFR1910.119): Not regulated.
STATE REGULATIONS:
California Proposition 65:
Known to the state of California to cause the following:
Oxytetracycline hydrochloride (internal use)
Developmental toxicity (Oct 01, 1991)
CANADIAN REGULATIONS:
WHMIS CLASSIFICATION: Not determined.
EUROPEAN REGULATIONS:
EC CLASSIFICATION (CALCULATED): Not determined.
GERMAN REGULATIONS:
WATER HAZARD CLASS (WGK):
STATE OF CLASSIFICATION: Annex 3
CLASSIFICATION UNDER HAZARD TO WATER: 2
NATIONAL INVENTORY STATUS:
U.S. INVENTORY (TSCA): Listed on inventory.
TSCA 12(b) EXPORT NOTIFICATION: Not listed.
Copyright 1984-2005 MDL Information Systems, Inc. All rights reserved.

Source: http://www.europharma.cl/download/hojas-seguridad/COD4-hoja-seguridad.pdf

Microsoft word - csteel-updatebleederseiph-june07-edited.doc

An update on “Bleeders” and that reported in Japan, Britain and South Africa, and less than that reported in Singapore, Hong Kong Defining a “bleeder”. and the USA. definition of a “bleeder” in various world. In Australia, bleeding is defined as the appearance of blood indicate that some degree of EIPH at both nostrils, irrespective of the ma

Delayed depolarization of the cog-wheel valve

The Journal of Experimental Biology 205, 1843–1851 (2002)Printed in Great Britain © The Company of Biologists Limited 2002JEB3996 Delayed depolarization of the cog-wheel valve and pulmonary-to-systemic shunting in alligators Douglas A. Syme1,*, Kurt Gamperl2,† and David R. Jones2,‡1 Department of Biological Sciences, 2500 University Drive NW, University of Calgary, Calgary, Alberta,

Copyright © 2010-2014 Sedative Dosing Pdf